Managing benign prostatic hyperplasia.
Medical and surgical options for the treatment of benign prostatic hyperplasia have expanded in recent years. Saw palmetto, the most widely used complementary medication, is less effective than standard medical therapy but has fewer side effects. Although non-selective alpha blockers provide rapid relief of symptoms and are relatively inexpensive, they can cause dizziness and orthostatic hypotension. These effects occur less often with tamsulosin, a more selective alpha blocker. Finasteride, a 5alpha-reductase inhibitor, slowly reduces prostatic volume but is not as effective as alpha blockers, especially in men with a smaller prostate. Dutasteride, a new 5alpha-reductase inhibitor, has recently been labeled for the treatment of benign prostatic hyperplasia. Surgery may be appropriate initial treatment in patients with severe symptoms who are not at high risk for complications. Surgery may also be indicated in patients who have failed medical therapy or have recurrent infection, hematuria, or renal insufficiency. Transurethral resection of the prostate is effective in most patients, but it carries some risk of sexual dysfunction, incontinence, and bleeding. Surgical procedures that use thermal microwave or laser energy to reduce hyperplastic prostate tissue have recently become available. In general, the newer procedures are less expensive than transurethral resection of the prostate and have fewer complications; however, the need for retreatment is somewhat greater with these less invasive techniques.
Department of Family Medicine at Ohio State University College of Medicine and Public Health, Thomas E. Rardin Family Practice Center, Columbia 43201, USA. dull-1@medctr.osu.edu
Pamela
P
Dull
Robert W
RW
Reagan
Robert R
RR
Bahnson
D000529:Complementary Therapies; D017292:Doxazosin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010173:Palpation; D011468:Prostatectomy / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000628:therapy*; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin; D020728:Transurethral Resection of Prostate; D014556:Urine / Q000737:chemistry
D013449:Sulfonamides; D000077409:Tamsulosin; D017292:Doxazosin